Dr. Shaw is being recognized for her "groundbreaking work in defining ALK- and ROS1-positive lung cancers," officials said.
Advertisement
A recent study may provide a "clearer, more individualized" understanding of progression risk after discontinuation.
Margarita Majem, MD, PhD, presented the results as a late-breaking abstract during the European Lung Cancer Congress 2025.
PALOMA-2 used data from PALOMA-3 to evaluate subcutaneous versus intravenous amivantamab for EGFR-mutated NSCLC.
The phase 3 DeLLphi-304 trial of tarlatamab versus standard-of-care chemotherapy has met its primary end point.
The session covered everything from new actionable immune checkpoints to vaccines, cellular therapies, and bispecifics.
Dr. Ladanyi reflects on genetic hotspot mutations that have not been previously well characterized in lung adenocarcinoma.
Martin Reck, MD, PhD, reflects on key updates in stage III NSCLC from the European Lung Cancer Congress 2025.
Stephen V. Liu, MD, weighs in on the data from the preplanned interim analysis that was recently published in The Lancet.
Suresh Senan, MRCP, FRCR, PhD, presented the data at the European Lung Cancer Congress 2025 in Paris, France.
Martin Reck, MD, PhD, presented the final analysis at the European Lung Cancer Congress 2025.
Roundtable Discussions
Expert Interviews
Conference Coverage
Find key news in thoracic oncology from the 61st Annual Meeting of the Society of Thoracic Surgeons.
Find the latest news and updates on lung cancer from the ESMO Congress 2024.
Find the latest updates on lung cancer treatment and research from the IASLC 2024 World Conference on Lung Cancer.
Find the latest updates on lung cancer treatment and research from the 2024 ASCO Annual Meeting.
Our editors detail the latest data and innovations in the lung cancer space presented at ATS 2024.
Our editors provide coverage on the development of innovative cancer therapeutics, as presented at ESMO TAT 2024.
Our editors deliver in-depth coverage of NACLC 2023, a premier event offering the latest data on lung cancer advancements.
Our editors provide comprehensive coverage of ESMO Congress 2023, with a focus on lung cancer.
Our editors detail the latest data and innovations in the lung cancer space, as presented at WCLC 2023.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.